Therapy with biological agents in juvenile-onset ankylosing spondylarthritis

Revista Romana de PEDIATRIE | Volumul LXI, Nr. 3, An 2012

ISSN 1454-0398 | e-ISSN 2069-6175
ISSN-L 1454-0398
DOI: 10.37897/RJP

National Awards “Science and Research”

NEW! RJP has announced the annually National Award for "Science and Research" for the best scientific articles published throughout the year in the official journal.

ICMJE- Recommendations

Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals.

Promoting Global Health

The published medical research literature is a global public good. Medical journal editors have a social responsibility to promote global health by publishing, whenever possible, research that furthers health worldwide.

D.A. Chiran, Evelina Moraru, Laura Marinela Ailioaie and C. Ailioaie

REZUMAT

Ankylosing spondylarthritis is an immune-mediated inflammatory disease, which includes axial and peripheral arthritis, inflammation of the site where tendons and joint capsules attaches to the bone and degeneration of the sacroiliac joint and the spinal cord joints, leading to progressive spinal fusions. Introduction of new immunomodulatory molecules into therapy aiming at interleukins, such as the tumor necrosis factor alpha, was considered a major breakthrough in the treatment of severe ankylosing spondylarthritis. This case illustrates the particular evolution of the clinical manifestations in correlation with joint trauma, gastrointestinal infection and the devastating consequences of active HLA-B27 positive ankylosing spondylarthritis with juvenile onset.

Key words: spondylarthritis, enthesitis, ankylosing, juvenile, biological agents

Full text | PDF